Article info
Review
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
- Correspondence to Professor Paul Emery, Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds LS7 4SA, UK; p.emery{at}leeds.ac.uk
Citation
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
Publication history
- Received February 18, 2013
- Revised June 20, 2013
- Accepted July 9, 2013
- First published August 5, 2013.
Online issue publication
November 04, 2013
Article Versions
- Previous version (5 August 2013).
- Previous version (10 August 2013).
- Previous version (17 September 2013).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online supplement
- Data supplement 2 - Online supplement
- Data supplement 3 - Online supplement
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/